Triazavirin (riamilovir)

Instructions for Triazavirin (riamilovir)

Description Triazavirin

The capsules are solid gelatin No. 1, the body is yellow and the lid is red; the capsules contain microcrystalline powder or granules of yellow or yellow-green color.

Active substances
Riamylovir

Release Form
Capsules

Composition
Capsules - 1 caps.:

Active ingredients:
triazavirin - 250 mg;

Auxiliary substances: Triazavirin
calcium stearate - 2 mg;
capsule body: titanium dioxide, quinoline yellow dye, sunset yellow dye, medical gelatin;
capsule cover: titanium dioxide, azorubin dye, gelatin medical.
20 capsules in an outline box.

Pharmacological effect

The active ingredient of the drug Triazavirin is a synthetic analog of guanine, the main component of purine nucleosides, and has a pronounced antiviral effect. Its antiviral activity is widely covered by viruses containing RNA with phosphokinase (PHk). Triazavirin's primary mechanism of action is inhibition of viral RNA synthesis and replication of genome fragments.

Pharmacokinetics riamilovir

When taken by mouth, the drug is quickly absorbed by the gastrointestinal tract. The maximum concentration (Cmax) in the blood is reached in 1-1.5 hours. The average Cmax at the recommended dose is about 4.8 mcg/mL. The area under the pharmacokinetic concentration-time (AUC) curve in blood is 12.8 mcg/h×mL. Half-life (T1/2) takes one to 1.5 hours. About 15 to 45% of the drug is excreted unchanged via the kidneys. Estimated drug clearance is an average of 246 mL/min.

Testimony Triazavirin

It is used to treat influenza in adults. It can be combined with the use of symptomatic drugs, if necessary.